|Day Low/High||171.89 / 174.70|
|52 Wk Low/High||130.09 / 181.81|
Some tried-and-true indicators show what's really going on with the market.
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval
Tom Price will now head the Department of Health and Human Services.
Interpublic and United Parcel raise dividends, and a recap of notable dates.
When bond yields rise, the economy roars and it's game on for industrials, banks and retailers, says Jim Cramer.
Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.
Jim Cramer likes European banks, plus Banco Santander, and New York Community Bancorp, too.
Jim Cramer takes a closer look at the risks: Don't measure 'Trump per share,' measure actual earnings per share.
Intravenous Administration Puts Delivery in Hands of Healthcare Provider
Would get drugs to market faster and possibly more cheaply.
The outcome of the so-called 'FOURIER' trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha.
Generics for drugs facing shortages or having few manufacturers is bill's focus.
Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint
Cytokinetics, Achillion and Qiagen were among the biotech stock movers in premarket trading on Thursday.
The Fed is simply not a market catalyst this time.
Biotech and drugs stocks are soaring Tuesday after President Donald Trump met with CEOs of the biotech and pharma industries Tuesday.
Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.
We are moderately overbought, both on a short-term and an intermediate-term basis.
Buckle in for a busy week filled with bellwether earnings reports, monetary policy decisions, and closely scrutinized economic numbers.
First Adalimumab Biosimilar Candidate Recommended for EMA Approval
There's not much reason to be bullish on these stocks.